Melanotan-1 · Research brief
Is Melanotan-1 FDA Approved Status — Regulatory Facts
Short answer
Melanotan-1 has never been approved by the FDA for any use. Clinical, cosmetic, or otherwise. This isn't a temporary regulatory hold or a pending approval scenario. As of 2026, no active Investigational New Drug (IND) applications exist for Melanotan-1 in the United States, and the compound has never progressed beyond early Phase II trials that concluded more than two decades…
Key takeaways
- Melanotan-1 fda approved status is limited to Scenesse implant for EPP only. No injectable form has FDA approval for any use.
- Injectable Melanotan-1 sold online is classified as an unapproved new drug under 21 USC §355, making its sale for human consumption illegal.
- Scenesse's FDA approval does not extend to compounded versions, off-label prescribing for tanning, or any formulation outside the 16mg controlled-release implant.
- Clinical trials for injectable Melanotan-1 were discontinued in the early 2000s due to adverse event profiles and lack of commercial viability. No active development pipeline exists as of 2026.
- The biological mechanism (MC1R agonism triggering eumelanin synthesis) is identical across formulations, but regulatory approval requires manufacturing standards, sterility verification, and clinical trial evidence that online peptides do not meet.
- Purchasing Melanotan-1 for personal use carries legal risk (possession of an unapproved drug) and health risk (no potency verification, sterility testing, or quality control).
Melanotan-1 has never been approved by the FDA for any use. Clinical, cosmetic, or otherwise. This isn't a temporary regulatory hold or a pending approval scenario. As of 2026, no active Investigational New Drug (IND) applications exist for Melanotan-1 in the United States, and the compound has never progressed beyond early Phase II trials that concluded more than two decades ago. Yet online retailers continue marketing it as a 'tanning peptide' or 'skin protection compound,' creating dangerous confusion about its legal status and safety profile. The gap between what people assume about Melanotan-1 and what the regulatory record actually shows is wider than most realise.
We've worked with research institutions procuring peptides for legitimate preclinical work, and the Melanotan-1 fda approved status question surfaces constantly. Often from individuals who encountered the compound through non-medical channels and now want clarity on whether they're using something legal or safe. The answer requires understanding not just FDA classification, but how peptide regulation functions when compounds exist in a grey zone between abandoned drug development and active black-market distribution.
Is Melanotan-1 FDA approved for any medical or cosmetic use?
No. Melanotan-1 (afamelanotide) does not hold FDA approval for tanning, photoprotection, or any other indication outside the distinct FDA-approved drug Scenesse, which uses a controlled-release implant formulation specifically for erythropoietic protoporphyria (EPP). Melanotan-1 as a standalone injectable peptide. The form sold online. Is not approved, has no legal prescribing pathway, and exists exclusively as a research chemical with no authorised human use.
The Regulatory Status of Melanotan-1 vs Scenesse
Melanotan-1 fda approved status depends entirely on formulation and indication. The confusion stems from one narrow FDA approval: Scenesse (afamelanotide 16mg implant), approved in 2019 for adult patients with erythropoietic protoporphyria (EPP). Scenesse is a biodegradable subcutaneous implant that releases afamelanotide. The synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). Over 60 days. It is not available by prescription for tanning, cosmetic darkening, or general photoprotection. The FDA approval is disease-specific, and the implant cannot be compounded, sold as an injectable, or prescribed off-label for cosmetic indications.
Every other form of Melanotan-1. Lyophilised powder sold online, reconstituted vials marketed as 'research peptides,' or pre-mixed injectables. Falls outside FDA oversight entirely. These products are neither approved drugs nor regulated dietary supplements. The FDA classifies them as unapproved new drugs under 21 USC §355, meaning their sale for human consumption violates federal law. The Melanotan-1 fda approved status for injectable forms is unambiguous: there is none. Vendors circumvent enforcement by labelling products 'for research purposes only' and disclaiming human use, but that label holds no legal weight once the product is marketed with dosing instructions, tanning protocols, or before-and-after photos.
The biological mechanism is identical across formulations. Afamelanotide binds to melanocortin-1 receptors (MC1R) on melanocytes, triggering eumelanin synthesis independent of UV exposure. But regulatory approval hinges on manufacturing standards, dosage consistency, sterility verification, and clinical trial evidence. Scenesse meets those requirements for EPP treatment. Online Melanotan-1 does not meet them for any use.
Why Melanotan-1 Never Advanced Beyond Early Trials
Melanotan-1 entered clinical development in the 1990s through trials conducted at the University of Arizona, initially targeting photoprotection and skin cancer risk reduction in fair-skinned populations. Early Phase I and Phase II studies demonstrated melanogenic activity. Participants experienced skin darkening without UV exposure. But the program stalled for reasons unrelated to efficacy. The primary obstacles were adverse event profile and commercial viability. Nausea, facial flushing, and spontaneous erections (in male participants) occurred at therapeutic doses, driven by melanocortin receptor cross-reactivity. MC1R activation produces melanin, but Melanotan-1 also weakly activates MC3R and MC4R, which regulate appetite, sexual function, and vascular tone.
By the early 2000s, pharmaceutical sponsors had shifted focus to Melanotan-2 (a cyclic analog with higher potency and shorter half-life) and afamelanotide implant formulations, which offered controlled release and reduced systemic side effects. Melanotan-1 injectable development was effectively abandoned. No FDA New Drug Application (NDA) was ever filed for Melanotan-1 in injectable form. The compound's Melanotan-1 fda approved status remained 'unapproved investigational drug'. A classification that persists in 2026.
Our team has reviewed the clinical trial registry for active afamelanotide studies. As of March 2026, no U.S.-based trials are recruiting for Melanotan-1 outside the existing Scenesse indication. European trials exploring afamelanotide for vitiligo and polymorphous light eruption exist but use the implant formulation, not injectable peptide. The injectable form has no active development pipeline, no sponsor, and no path to FDA review.
Melanotan-1 FDA Approved Status: Comparison
| Formulation | FDA Status | Legal Availability | Approved Indication | Manufacturing Oversight | Professional Assessment |
|---|---|---|---|---|---|
| Scenesse (afamelanotide 16mg implant) | FDA-approved (2019) | Prescription only, specialty pharmacies | Erythropoietic protoporphyria (EPP) | Full cGMP, batch testing, traceability | Only FDA-recognised form of afamelanotide. Cannot be compounded or prescribed off-label for cosmetic use |
| Injectable Melanotan-1 (lyophilised peptide) | Unapproved new drug | Illegal for human use; sold as 'research chemical' | None | No FDA oversight; no sterility or potency guarantees | Identical active molecule to Scenesse but lacks regulatory approval, standardised dosing, or safety verification |
| Compounded afamelanotide | Not approved; no 503B exemption | Illegal. Compounding of Scenesse is prohibited | None | Prohibited under FDA compounding rules | Compounding pharmacies cannot legally produce afamelanotide in any form. Scenesse's approval explicitly excludes compounding |
| Melanotan-2 (bremelanotide analog) | Unapproved new drug | Illegal for human use; sold as 'research chemical' | None | No FDA oversight | Structurally distinct from Melanotan-1; higher MC4R affinity; associated with more severe cardiovascular side effects |
What If: Melanotan-1 Scenarios
What If I'm Already Using Melanotan-1 I Purchased Online?
Stop immediately and discard any remaining product. You're using an unapproved drug with no sterility verification, no potency testing, and no legal recourse if adverse effects occur. The lyophilised peptides sold as 'Melanotan-1' undergo no FDA batch review. Contamination with bacterial endotoxins, incorrect peptide sequences, or degraded product is undetectable without mass spectrometry. If you've experienced side effects (nausea, flushing, darkening moles, visual changes), contact a physician and bring the product packaging if possible. Do not assume the product contains what the label claims.
What If My Dermatologist Mentions Scenesse — Is That the Same as Melanotan-1?
Scenesse contains afamelanotide, which is the pharmaceutical name for synthetic Melanotan-1. The active molecule is identical, but Scenesse is a controlled-release implant approved exclusively for erythropoietic protoporphyria (EPP), not for cosmetic tanning or general photoprotection. Your dermatologist cannot prescribe Scenesse off-label for tanning. The drug is dispensed only through a restricted REMS program requiring confirmed EPP diagnosis. If you're interested in photoprotection, discuss FDA-approved options like high-SPF sunscreens, oral polypodium leucotomos (Heliocare), or behavioural UV avoidance strategies.
What If I Want to Use Melanotan-1 for a Legitimate Medical Reason?
The only legal pathway is enrollment in a clinical trial. Search ClinicalTrials.gov using the term 'afamelanotide' and filter by recruiting status. As of 2026, trials exist for vitiligo, polymorphous light eruption, and photodermatoses, but they use the Scenesse implant. Not injectable peptide. If no active trials match your condition, no legal access exists. Compounding pharmacies cannot produce afamelanotide under 503A or 503B exemptions because Scenesse's approval explicitly prohibits compounding. Importing Melanotan-1 from overseas suppliers violates FDA import restrictions under 21 USC §381.
The Blunt Truth About Melanotan-1 FDA Approved Status
Here's the honest answer: if you're buying Melanotan-1 online and injecting it, you're using a product that has never been through the safety and efficacy review required for FDA approval. The Melanotan-1 fda approved status for injectable forms doesn't exist because no manufacturer has ever completed the clinical trial pathway necessary to file a New Drug Application. Scenesse's approval is irrelevant to the injectable peptide market. It's a different formulation, a different indication, and a different regulatory category entirely. The vendors selling lyophilised Melanotan-1 are not operating in a grey area. They're selling unapproved drugs, and the 'research purposes only' disclaimer is legal theatre designed to avoid FDA enforcement, not a legitimate carve-out.
The mechanism works. MC1R agonism does trigger melanogenesis, and that's not disputed. What's disputed is whether a product with no sterility testing, no potency verification, and no adverse event monitoring should be injected subcutaneously by individuals with no medical oversight. The answer from every regulatory body that has reviewed this question is no. If your goal is photoprotection, the evidence for oral antioxidants like polypodium leucotomos and nicotinamide is stronger, safer, and doesn't require injecting an unapproved peptide purchased from an unregulated supplier. If your goal is cosmetic tanning, you're accepting significant legal and health risk for an outcome achievable through FDA-approved spray tans or self-tanning lotions.
Real Peptides supplies research-grade peptides for preclinical work under strict quality controls, but Melanotan-1 fda approved status remains unchanged regardless of supplier. High-purity synthesis doesn't confer regulatory approval. It confirms the molecule's identity and concentration, which is necessary but not sufficient for human use. Our full peptide collection includes compounds with established safety profiles in ongoing research, but afamelanotide in injectable form is not among them because the regulatory pathway does not exist.
The Melanotan-1 fda approved status is unambiguous. No approval exists for injectable forms. No active development pipeline exists. No legal prescribing pathway exists outside Scenesse for EPP. If you're considering Melanotan-1 for any reason, the legally and medically appropriate action is to wait for FDA-approved alternatives or participate in an active clinical trial. Anything else is assumption of risk without informed consent. And that's not a foundation for safe peptide use.
References
Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.
- Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
- Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
- A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
- Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
- Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
- Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
- Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA